Eric Coldwell
Stock Analyst at Baird
(5.00)
# 9
Out of 4,791 analysts
184
Total ratings
55.24%
Success rate
124.52%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Outperform | $190 → $191 | $167.96 | +13.72% | 9 | Mar 20, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $221 → $203 | $168.70 | +20.33% | 19 | Mar 4, 2025 | |
| OMI Owens & Minor | Maintains: Neutral | $10 → $11 | $9.16 | +20.09% | 17 | Mar 3, 2025 | |
| AHCO AdaptHealth | Maintains: Outperform | $14 → $16 | $10.81 | +48.01% | 10 | Feb 27, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $177 → $173 | $149.28 | +15.89% | 13 | Feb 20, 2025 | |
| PINC Premier | Maintains: Neutral | $20 → $19 | $19.55 | -2.81% | 7 | Feb 5, 2025 | |
| MEDP Medpace Holdings | Maintains: Neutral | $354 → $362 | $311.23 | +16.31% | 17 | Jan 27, 2025 | |
| IQV IQVIA Holdings | Maintains: Neutral | $212 → $210 | $174.37 | +20.43% | 16 | Jan 21, 2025 | |
| FTRE Fortrea Holdings | Downgrades: Neutral | $28 → $25 | $7.51 | +232.89% | 7 | Dec 6, 2024 | |
| MCK McKesson | Upgrades: Outperform | $531 → $688 | $693.53 | -0.80% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $282 → $289 | $236.37 | +22.27% | 12 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $137 | $138.67 | -1.20% | 11 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $51 | $11.18 | +356.17% | 16 | Apr 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $58.04 | -22.47% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $68.07 | -3.04% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $1.38 | +3,245.45% | 4 | Nov 10, 2017 |
Quest Diagnostics
Mar 20, 2025
Maintains: Outperform
Price Target: $190 → $191
Current: $167.96
Upside: +13.72%
ICON Public Limited Company
Mar 4, 2025
Maintains: Neutral
Price Target: $221 → $203
Current: $168.70
Upside: +20.33%
Owens & Minor
Mar 3, 2025
Maintains: Neutral
Price Target: $10 → $11
Current: $9.16
Upside: +20.09%
AdaptHealth
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $10.81
Upside: +48.01%
Charles River Laboratories International
Feb 20, 2025
Maintains: Neutral
Price Target: $177 → $173
Current: $149.28
Upside: +15.89%
Premier
Feb 5, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $19.55
Upside: -2.81%
Medpace Holdings
Jan 27, 2025
Maintains: Neutral
Price Target: $354 → $362
Current: $311.23
Upside: +16.31%
IQVIA Holdings
Jan 21, 2025
Maintains: Neutral
Price Target: $212 → $210
Current: $174.37
Upside: +20.43%
Fortrea Holdings
Dec 6, 2024
Downgrades: Neutral
Price Target: $28 → $25
Current: $7.51
Upside: +232.89%
McKesson
Nov 7, 2024
Upgrades: Outperform
Price Target: $531 → $688
Current: $693.53
Upside: -0.80%
Oct 25, 2024
Maintains: Outperform
Price Target: $282 → $289
Current: $236.37
Upside: +22.27%
Aug 15, 2024
Maintains: Outperform
Price Target: $130 → $137
Current: $138.67
Upside: -1.20%
Apr 1, 2022
Downgrades: Neutral
Price Target: $51
Current: $11.18
Upside: +356.17%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $58.04
Upside: -22.47%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $68.07
Upside: -3.04%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $1.38
Upside: +3,245.45%